ZA200410135B - Infertility treatment with exemestane - Google Patents
Infertility treatment with exemestane Download PDFInfo
- Publication number
- ZA200410135B ZA200410135B ZA200410135A ZA200410135A ZA200410135B ZA 200410135 B ZA200410135 B ZA 200410135B ZA 200410135 A ZA200410135 A ZA 200410135A ZA 200410135 A ZA200410135 A ZA 200410135A ZA 200410135 B ZA200410135 B ZA 200410135B
- Authority
- ZA
- South Africa
- Prior art keywords
- exemestane
- host
- female
- female host
- administered
- Prior art date
Links
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 title claims description 29
- 229960000255 exemestane Drugs 0.000 title claims description 29
- 208000000509 infertility Diseases 0.000 title claims description 13
- 230000036512 infertility Effects 0.000 title claims description 13
- 231100000535 infertility Toxicity 0.000 title claims description 13
- 238000000034 method Methods 0.000 claims description 22
- 230000003325 follicular Effects 0.000 claims description 19
- 230000002611 ovarian Effects 0.000 claims description 12
- 230000000638 stimulation Effects 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 230000027758 ovulation cycle Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 5
- 206010058359 Hypogonadism Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims description 4
- 230000016087 ovulation Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000014654 Aromatase Human genes 0.000 description 5
- 108010078554 Aromatase Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- 229960005471 androstenedione Drugs 0.000 description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000005670 Anovulation Diseases 0.000 description 2
- 206010002659 Anovulatory cycle Diseases 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- 238000005899 aromatization reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
- 108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39332002P | 2002-07-02 | 2002-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200410135B true ZA200410135B (en) | 2006-07-26 |
Family
ID=30115565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200410135A ZA200410135B (en) | 2002-07-02 | 2005-12-15 | Infertility treatment with exemestane |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1531829A2 (pt) |
| JP (1) | JP2005536490A (pt) |
| KR (1) | KR20050077045A (pt) |
| CN (1) | CN1665516A (pt) |
| AU (1) | AU2003247404A1 (pt) |
| BR (1) | BR0312393A (pt) |
| CA (1) | CA2491372A1 (pt) |
| IL (1) | IL165813A0 (pt) |
| MX (1) | MXPA05000251A (pt) |
| PL (1) | PL373219A1 (pt) |
| WO (1) | WO2004004634A2 (pt) |
| ZA (1) | ZA200410135B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102432156B1 (ko) * | 2020-05-18 | 2022-08-11 | 제주대학교 산학협력단 | 화학물질을 포함하는 어류의 성 성숙 제어용 조성물 및 이를 이용한 어류의 성 성숙 제어방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60229047D1 (de) * | 2001-04-17 | 2008-11-06 | Ares Trading Sa | Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit |
| ATE363906T1 (de) * | 2001-04-17 | 2007-06-15 | Ares Trading Sa | Aromatase hemmung zur steigerung der implantationsrate |
-
2003
- 2003-07-02 PL PL03373219A patent/PL373219A1/xx not_active Application Discontinuation
- 2003-07-02 MX MXPA05000251A patent/MXPA05000251A/es unknown
- 2003-07-02 JP JP2004519563A patent/JP2005536490A/ja active Pending
- 2003-07-02 EP EP03762980A patent/EP1531829A2/en not_active Withdrawn
- 2003-07-02 BR BR0312393-6A patent/BR0312393A/pt not_active IP Right Cessation
- 2003-07-02 KR KR1020057000051A patent/KR20050077045A/ko not_active Application Discontinuation
- 2003-07-02 WO PCT/US2003/016252 patent/WO2004004634A2/en active Application Filing
- 2003-07-02 CN CN038157306A patent/CN1665516A/zh active Pending
- 2003-07-02 CA CA002491372A patent/CA2491372A1/en not_active Abandoned
- 2003-07-02 AU AU2003247404A patent/AU2003247404A1/en not_active Abandoned
-
2004
- 2004-12-16 IL IL16581304A patent/IL165813A0/xx unknown
-
2005
- 2005-12-15 ZA ZA200410135A patent/ZA200410135B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05000251A (es) | 2005-07-15 |
| CA2491372A1 (en) | 2004-01-15 |
| WO2004004634A2 (en) | 2004-01-15 |
| PL373219A1 (en) | 2005-08-22 |
| WO2004004634A3 (en) | 2004-04-08 |
| AU2003247404A1 (en) | 2004-01-23 |
| JP2005536490A (ja) | 2005-12-02 |
| BR0312393A (pt) | 2005-04-12 |
| CN1665516A (zh) | 2005-09-07 |
| IL165813A0 (en) | 2006-01-15 |
| EP1531829A2 (en) | 2005-05-25 |
| KR20050077045A (ko) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mitwally et al. | Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovary syndrome | |
| US4835147A (en) | Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction | |
| US6451779B1 (en) | Composition and method for contraception and treatment of tumors of the mammary glands | |
| AU743277B2 (en) | Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor | |
| CZ298738B6 (cs) | Prostředek pro léčbu hypertrofie prostaty a rakoviny prostaty | |
| WO2011058557A1 (en) | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes | |
| Seal | The practical management of hormonal treatment in adults with gender dysphoria | |
| ZA200410135B (en) | Infertility treatment with exemestane | |
| US20030144259A1 (en) | Breast cancer hormonal therapy | |
| Brodie et al. | Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors | |
| MXPA04002125A (es) | Uso de la hl en la hiperestimulacion ovarica controlada. | |
| EP1383578B1 (en) | Single dose aromatase inhibitor for treating infertility | |
| UA51627C2 (uk) | Відновлення тонічної секреції естрогену з яєчників для довгочасних схем лікування | |
| Chung et al. | Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development | |
| Purohit et al. | Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy | |
| Kini | Polycystic ovary syndrome: diagnosis and management of related infertility | |
| US20220110947A1 (en) | Cyproterone acetate compositions and uses thereof | |
| Ziporyn | LHRH: clinical applications growing | |
| Bulun et al. | Medical therapies: aromatase inhibitors | |
| EP1322333A2 (en) | Composition for combined use of aromatase inhibitors | |
| Yousif | Corticosteroids and Duration of Medical Induction for Mid-Trimester Abortion | |
| US20100087407A1 (en) | use of aromatase inhibitors | |
| Shrivastav | Aromatase Inhibitors—Their Role in the Treatment of Infertility | |
| Sterrenburg et al. | Drugs in reproductive medicine | |
| RU2289409C1 (ru) | Способ реабилитации женщин после медикаментозного прерывания беременности |